Sharon A. Riddler
Advanced in Sepsis

Dr. Sharon A. Riddler

Infectious Disease
UPMC
Center For Care Of Infectious Diseases (Ccid)
3601 5th Avenue, Suite 700, 
Pittsburgh, PA 
On Staff At
Accepting New Patients

Advanced in Sepsis
UPMC
Center For Care Of Infectious Diseases (Ccid)
3601 5th Avenue, Suite 700, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sharon Riddler, MD, is certified in infectious disease and internal medicine by the American Board of Internal Medicine. She practices at University of Pittsburgh Physicians, Department of Medicine, Division of Infectious Disease and is affiliated with UPMC Magee-Womens Hospital, and UPMC Presbyterian. She completed her fellowship at University of Pittsburgh School of Medicine, residency at University of Missouri Kansas City, and medical degree at Medical College of Wisconsin. LGBTQIA+ Affirming: This provider has completed training on how to create a safe, comfortable, and welcoming environment for LGBTQIA+ patients. This provider may or may not offer LGBTQIA+ specific medical or surgical care. Please ask when scheduling. Are you already a patient of this provider and have a MyUPMC account? Log in to MyUPMC to schedule.

Dr. Riddler is rated as an Advanced provider by MediFind in the treatment of Sepsis. Her top areas of expertise are HIV/AIDS, Sepsis, Myelitis, and AIDS Dementia Complex.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Sepsis.

Graduate Institution
Medical College Of Wisconsin
Residency
University of Missouri Kansas City
Specialties
Infectious Disease
Licenses
Specialist in PA
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
University of Pittsburgh School of Medicine
Hospital Affiliations
Upmc Presbyterian Shadyside
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

CENTER FOR CARE OF INFECTIOUS DISEASES (CCID)
3601 5th Avenue, Suite 700, Pittsburgh, PA 15213
Call: 412-438-2347

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) Vaccine, in HIV-1 Infected Adults on Suppressive ART
Safety, Tolerability and Immunogenicity of Recombinant HIV Envelope Protein VRC-HIVRGP096-00-VP (Trimer 4571) Vaccine, in HIV-1 Infected Adults on Suppressive ART
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
Intervention Type: Biological
Study Drug: Trimer 4571 vaccine
Study Phase: Phase 1
A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
A Phase I Study to Evaluate the Safety, Tolerability and Immunogenicity of a Therapeutic HIV Vaccine Composed of Autologous Dendritic Cells Loaded With Autologous Inactivated Whole Virus or Conserved Peptides in ART-treated HIV-infected Adults
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Biological
Study Drugs: a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigena1DC
Study Phase: Phase 1
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Enema Administered Rectally to HIV-1 Seronegative Adults
A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Enema Administered Rectally to HIV-1 Seronegative Adults
Enrollment Status: Terminated
Publish Date: July 06, 2023
Intervention Type: Drug, Other
Study Phase: Phase 1
APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnostic Testing
APT-POCT-01: An Open Label, Pharmacokinetic Study of Plasma/Urine/Salivary Drug Concentrations Over Fourteen Days Following Drug Intake Cessation, In HIV-Uninfected Healthy Volunteers Dosing to Steady-state to Further Development of Point of Care Diagnostic Testing
Enrollment Status: Completed
Publish Date: March 03, 2022
Intervention Type: Drug
Study Drugs: Dolutegravir, Emtricitabine/Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, Lamivudine
Study Phase: Early Phase 1
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987
A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987
Enrollment Status: Completed
Publish Date: April 11, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

59 Total Publications

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.
Journal: British journal of clinical pharmacology
Published: September 03, 2025
View All 59 Publications
Similar Doctors
Elite in Sepsis
Dr. John W. Mellors
Infectious Disease
Elite in Sepsis
Dr. John W. Mellors
Infectious Disease

University Of Pittsburgh Physicians, Department Of Medicine, Division Of Infectious Disease

3601 5th Avenue, Falk Clinic Suite 700, 
Pittsburgh, PA 
 (0.1 miles away)
412-946-2738
Languages Spoken:
English, French
See accepted insurances

John Mellors, MD, specializes in infectious diseases and is board-certified in infectious disease and internal medicine by the American Board of Internal Medicine. He is affiliated with UPMC Presbyterian. Dr. Mellors received his medical degree from Dartmouth College Geisel School of Medicine and completed his residency and fellowship at Yale New Haven Hospital. Dr. Mellors is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are HIV/AIDS, Sepsis, COVID-19, and Severe Acute Respiratory Syndrome (SARS).

Lee H. Harrison
Distinguished in Sepsis
Dr. Lee H. Harrison
Infectious Disease
Distinguished in Sepsis
Dr. Lee H. Harrison
Infectious Disease

University Of Pittsburgh Physicians Division Of Infectious Diseases

3601 5th Avenue, Floor 7, 
Pittsburgh, PA 
 (0.1 miles away)
412-648-6401
Languages Spoken:
English, French, German, Italian, Portuguese, Spanish
See accepted insurances

Lee Harrison is an Infectious Disease provider in Pittsburgh, Pennsylvania. Dr. Harrison is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Strep Throat, Methicillin-Resistant Staphylococcus Aureus (MRSA), Sepsis, and Bacterial Meningitis.

Yohei Doi
Distinguished in Sepsis
Dr. Yohei Doi
Infectious Disease
Distinguished in Sepsis
Dr. Yohei Doi
Infectious Disease

University Of Pittsburgh Physicians, Department Of Medicine, Infectious Diseases

3601 5th Avenue, Suite 3A, 
Pittsburgh, PA 
 (0.1 miles away)
412-648-6401
Languages Spoken:
English, Japanese
See accepted insurances

Yohei Doi is an Infectious Disease provider in Pittsburgh, Pennsylvania. Dr. Doi is rated as an Advanced provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Pseudomonas Stutzeri Infections, Severe Acute Respiratory Syndrome (SARS), and Pneumonia.

VIEW MORE SEPSIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Riddler's expertise for a condition
ConditionClose
    • Distinguished
    • HIV/AIDS
      Dr. Riddler is
      Distinguished
      . Learn about HIV/AIDS.
      See more HIV/AIDS experts
    • Advanced
    • AIDS Dementia Complex
      Dr. Riddler is
      Advanced
      . Learn about AIDS Dementia Complex.
      See more AIDS Dementia Complex experts
    • AIDS Dysmorphic Syndrome
      Dr. Riddler is
      Advanced
      . Learn about AIDS Dysmorphic Syndrome.
      See more AIDS Dysmorphic Syndrome experts
    • Myelitis
      Dr. Riddler is
      Advanced
      . Learn about Myelitis.
      See more Myelitis experts
    • Sepsis
      Dr. Riddler is
      Advanced
      . Learn about Sepsis.
      See more Sepsis experts
    • Experienced
    • Chronic Spontaneous Urticaria (CSU)
      Dr. Riddler is
      Experienced
      . Learn about Chronic Spontaneous Urticaria (CSU).
      See more Chronic Spontaneous Urticaria (CSU) experts
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.